发布求助
文献互助 智能选刊 最新文献

Psoriasis forum最新文献

筛选
英文 中文
Biomarkers to Diagnose Early Arthritis in Patients With Psoriasis. 诊断银屑病患者早期关节炎的生物标志物
Psoriasis forum Pub Date : 2012-01-01
Ya-Hui Grace Chiu, Christopher T Ritchlin
{"title":"Biomarkers to Diagnose Early Arthritis in Patients With Psoriasis.","authors":"Ya-Hui Grace Chiu, Christopher T Ritchlin","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Psoriatic arthritis is a potentially destructive, inflammatory joint disease that affects 20% to 30% of patients with psoriasis. Psoriasis precedes the onset of joint inflammation by approximately 10 years, providing a unique opportunity to intervene and prevent or delay onset of musculoskeletal manifestations. The emergence of sensitive imaging modalities and cellular biomarkers may facilitate early identification of patients with psoriasis who have subclinical joint disease and might help stratify patients with an early onset of arthritis.</p><p><strong>Methods: </strong>The translational studies described herein are focused on the development of cellular biomarkers identified with flow cytometry and cell culture techniques in patients with psoriasis and psoriatic arthritis.</p><p><strong>Results and conclusion: </strong>The combination of power Doppler ultrasound imaging and cellular biomarkers (ie, CD16 and dendritic cell specific transmembrane protein) to diagnose early psoriatic arthritis and to stratify patients with established psoriatic arthritis provides a new opportunity to optimize treatment outcomes in this potentially disabling disease.</p>","PeriodicalId":90709,"journal":{"name":"Psoriasis forum","volume":"18 2","pages":"2-10"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4241968/pdf/nihms595092.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32841580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hydroxyurea for the Treatment of Psoriasis including in HIV-infected Individuals: A Review. 羟基脲治疗包括hiv感染者在内的银屑病的研究进展
Psoriasis forum Pub Date : 2011-01-01
Eric S Lee, Misha M Heller, Faranak Kamangar, Kelly Park, Wilson Liao, John Koo
{"title":"Hydroxyurea for the Treatment of Psoriasis including in HIV-infected Individuals: A Review.","authors":"Eric S Lee,&nbsp;Misha M Heller,&nbsp;Faranak Kamangar,&nbsp;Kelly Park,&nbsp;Wilson Liao,&nbsp;John Koo","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Hydroxyurea is a drug that has been long forgotten for the treatment of psoriasis. In addition to its anti-psoriatic effects, it has also been shown to have antiviral effects. This dual effect makes it a drug that dermatologists may want to consider when treating psoriasis in HIV-infected individuals. There are currently no studies that discuss the safety and efficacy of hydroxyurea in the treatment of psoriasis in this immunocompromised group; however, there are multiple reports that discuss the safety and efficacy of hydroxyurea in psoriasis and HIV separately. This review suggests that hydroxyurea is generally safe and effective. The main risk involves the hematologic adverse events (anemia, leukopenia, thrombocytopenia, and macrocytosis) which appear to be dose-dependent. Because of the common hematologic adverse events, hydroxyurea may be considered as a viable therapeutic option for patients with generalized psoriasis inadequately responsive to other safer options, whether the patient is HIV-positive or not.</p>","PeriodicalId":90709,"journal":{"name":"Psoriasis forum","volume":"17 3","pages":"180-187"},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4205952/pdf/nihms511276.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32773577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
How Long Does the Benefit of Biologics Last? An Update on Time To Relapse and Potential for Rebound of Biologic Agents for Psoriasis. 生物制剂的疗效能持续多久？关于银屑病生物制剂复发时间和反弹可能性的最新进展。
Psoriasis forum Pub Date : 2010-01-01
Monique Kamaria, Wilson Liao, J Y Koo
{"title":"How Long Does the Benefit of Biologics Last? An Update on Time To Relapse and Potential for Rebound of Biologic Agents for Psoriasis.","authors":"Monique Kamaria, Wilson Liao, J Y Koo","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The biologic agents vary considerably in terms of their long-term duration of effect. Using the definitions provided by the National Psoriasis Foundation Medical Board, the objective of this review was to compare all biologic agents with respect to time to relapse and potential for rebound. Overall, alefacept had the longest off-treatment benefit (29.9 weeks in Psoriasis Area and Severity Index [PASI] 75 responders), followed by ustekinumab (22 weeks), infliximab (19.5 weeks), adalimumab (18 weeks), etanercept (12.1 weeks in PASI 50 responders), and, lastly, efalizumab (9.6 weeks). Rebound was reported commonly for efalizumab (14%) and, extremely rarely, for etanercept (0.002%).</p>","PeriodicalId":90709,"journal":{"name":"Psoriasis forum","volume":"16 2","pages":"36-42"},"PeriodicalIF":0.0,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4205949/pdf/nihms515429.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32773127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Which Psoriasis Patients Develop Psoriatic Arthritis? 哪些银屑病患者会发展为银屑病关节炎?
Psoriasis forum Pub Date : 2010-01-01
Kristine Busse, Wilson Liao
{"title":"Which Psoriasis Patients Develop Psoriatic Arthritis?","authors":"Kristine Busse,&nbsp;Wilson Liao","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Psoriatic arthritis is a major comorbidity of psoriasis that significantly impairs quality of life and physical function. Because skin lesions classically precede joint symptoms, dermatologists are in a unique position to identify patients at risk for psoriatic arthritis before irreversible joint damage occurs. Here we review the literature to identify the clinical and genetic factors most highly associated with development of psoriatic arthritis, with the goal of assisting dermatologists in risk-stratifying their psoriasis patients.</p>","PeriodicalId":90709,"journal":{"name":"Psoriasis forum","volume":"16 4","pages":"17-25"},"PeriodicalIF":0.0,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4206220/pdf/nihms511217.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32773128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信